Avacta Therapeutics (AIM: AVCT) Result of Oversubscribed Fundraise - Share Talk

Avacta Therapeutics (AIM: AVCT) Result of Oversubscribed Fundraise

Avacta Group plc has raised £10 million through an oversubscribed placing and subscription, highlighting strong investor demand.

The new shares were issued at 63p each, with directors Richard Hughes and David Bryant participating via a £550,000 subscription, signalling internal confidence in the company.

As part of the fundraising, Zeus Capital will receive warrants over 4,364,457 shares (around 0.96% of the enlarged share capital), exercisable at 63p over five years.

The involvement of Zeus Capital and the director participation are classified as related party transactions, which independent directors have confirmed are fair and reasonable.

Admission of the new shares to AIM is expected on or around 7 April 2026, taking the total number of shares in issue to 456,288,511.

Director Subscriptions

As described in the Launch Announcement, certain Directors, being Richard Hughes and David Bryant (the “Subscribers”), have subscribed for 873,016 new Ordinary Shares at the Issue Price, representing an aggregate investment of approximately £550,000 pursuant to the Subscription.

Director

Position

Aggregate Subscription Amount

Number of Subscription Shares

Resultant Shareholding

% of Enlarged Share Capital

Richard Hughes

Non-Executive Director

£500,000

793,651

793,651

0.17

David Bryant

Non-Executive Director

£50,000

79,365

79,365

0.02

About Avacta – https://avacta.com/


Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned